Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: fludarabine phosphate, clofarabine, gemcitabine +4 | 1.00 |
| trials ClinicalTrials.gov | 18 Parkinson's trials, 3 stopped | 0.87 |
| literature PubMed | 1 Parkinson's papers of 216 | 0.91 |
| pathways Reactome | 10 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8926
Sealed predictions
- POLA1 in dopamine neurons, braak-0.09 (p 0.825) → +0.44 (p 0.240)receipt 8933
Swarm cases
receipt 8933: POLA1 in dopamine neurons, braak
- power
- full sample +0.19 (p 0.455, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.36 (p 0.145, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.34 (p 0.167, n 18). could be the mix.
- skeptic
- leave-one-out range +0.07 to +0.36, sign flips 0; without severely affected donors +0.19 (p 0.455, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for POLA1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts